Tempus AI (NASDAQ:TEM) Trading Up 1.1% – Should You Buy?

Tempus AI, Inc. (NASDAQ:TEM) shares shot up 1.1% during mid-day trading on Wednesday . The company traded as high as $74.68 and last traded at $72.01. 9,626,059 shares were traded during trading, a decline of 23% from the average session volume of 12,483,670 shares. The stock had previously closed at $71.21.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on TEM shares. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price objective on shares of Tempus AI in a research report on Tuesday, January 14th. William Blair downgraded shares of Tempus AI from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Bank of America raised their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Finally, Guggenheim began coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Tempus AI has an average rating of “Moderate Buy” and an average price target of $58.55.

Tempus AI Stock Up 2.8 %

The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The firm has a 50 day moving average of $44.89 and a two-hundred day moving average of $49.56.

Insider Activity

In other Tempus AI news, CEO Eric P. Lefkofsky sold 476,209 shares of the firm’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $49.84, for a total value of $23,734,256.56. Following the completion of the sale, the chief executive officer now owns 6,502,643 shares in the company, valued at approximately $324,091,727.12. This trade represents a 6.82 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David R. Epstein sold 620 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total value of $25,922.20. Following the sale, the director now owns 27,894 shares in the company, valued at approximately $1,166,248.14. This represents a 2.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,229,449 shares of company stock valued at $102,293,124.

Institutional Trading of Tempus AI

Several institutional investors have recently made changes to their positions in TEM. ARK Investment Management LLC lifted its holdings in shares of Tempus AI by 132.1% during the fourth quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock valued at $186,343,000 after acquiring an additional 3,141,487 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Tempus AI by 166.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after purchasing an additional 2,021,394 shares in the last quarter. Nikko Asset Management Americas Inc. lifted its holdings in Tempus AI by 166.0% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company’s stock valued at $109,352,000 after purchasing an additional 2,021,394 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Tempus AI by 86,947.2% in the fourth quarter. JPMorgan Chase & Co. now owns 1,653,896 shares of the company’s stock valued at $55,836,000 after buying an additional 1,651,996 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Tempus AI during the fourth quarter worth approximately $34,681,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.